Search

Your search keyword '"McMurray, John J.V."' showing total 828 results
Start Over Author "McMurray, John J.V." Search Limiters Full Text Search Limiters Peer Reviewed
828 results on '"McMurray, John J.V."'

1. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial

Author

Wang, Xiaowen, Lam, Carolyn S.P., Vaduganathan, Muthiah, Kondo, Toru, Yang, Mingming, Han, Yaling, Pham, Vinh Nguyen, Chiang, Chern-En, Kitakaze, Masafumi, Miao, Zi Michael, Jhund, Pardeep S., Desai, Akshay S., Inzucchi, Silvio E., de Boer, Rudolf A., Martinez, Felipe A., Kosiborod, Mikhail N., Hernandez, Adrian F., Claggett, Brian, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

2. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function

Author

Chatur, Safia, Vaduganathan, Muthiah, Claggett, Brian L., Mc Causland, Finnian R., Desai, Akshay S., Jhund, Pardeep S., de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe A., Shah, Sanjiv J., Sabatine, Marc S., Kober, Lars, Ponikowski, Piotr, Merkely, Bela, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.

Published
2023
Full Text
View/download PDF

4. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status

Author

Peikert, Alexander, Goyal, Parag, Vaduganathan, Muthiah, Claggett, Brian L., Kulac, Ian J., Miao, Zi Michael, Vardeny, Orly, Kosiborod, Mikhail N., Desai, Akshay S., Jhund, Pardeep S., Lam, Carolyn S.P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Hernandez, Adrian F., Shah, Sanjiv J., Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.

Published
2023
Full Text
View/download PDF

8. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction

Author

Inciardi, Riccardo M., Abanda, Martin, Shah, Amil M., Cikes, Maja, Claggett, Brian, Skali, Hicham, Vaduganathan, Muthiah, Prasad, Narayana, Litwin, Sheldon, Merkely, Bela, Kosztin, Annamaria, Nagy, Klaudia Vivien, Shah, Sanjiv J., Mullens, Wilfred, Zile, Michael R., Lam, Carolyn S.P., Pfeffer, Marc A., McMurray, John J.V., and Solomon, Scott D.

Published
2023
Full Text
View/download PDF

12. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

Author

Lanfear, David E., Njoroge, Joyce N., Adams, Kirkwood F., Anand, Inder, Fang, James C., Ramires, Felix, Sliwa-Hahnle, Karen, Badat, Aysha, Burgess, Lesley, Gorodeski, Eiran Z., Williams, Celeste, Diaz, Rafael, Felker, Gary M., McMurray, John J.V., Metra, Marco, Solomon, Scott, Miao, Zi Michael, Claggett, Brian L., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., and Teerlink, John R.

Published
2023
Full Text
View/download PDF

13. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum

Author

Butt, Jawad H., Docherty, Kieran F., Claggett, Brian L., Desai, Akshay S., Fang, James C., Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., Cabrera Honorio, Jose Walter, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Køber, Lars, Lam, Carolyn S.P., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Vardeny, Orly, O'Meara, Eileen, Saraiva, Jose F.K., Shah, Sanjiv J., Vaduganathan, Muthiah, Jhund, Pardeep S., Solomon, Scott D., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

14. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF

Author

Adamson, Carly, Welsh, Paul, Docherty, Kieran F., de Boer, Rudolf A., Diez, Mirta, Drożdż, Jarosław, Dukát, Andre, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Ljungman, Charlotta E.A., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Morrow, David A., Lindholm, Daniel, Hammarstedt, Ann, Boulton, David W., Greasley, Peter J., Langkilde, Anna Maria, Solomon, Scott D., Sattar, Naveed, McMurray, John J.V., and Jhund, Pardeep S.

Published
2023
Full Text
View/download PDF

18. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Author

Myhre, Peder L., Vaduganathan, Muthiah, Claggett, Brian L., Miao, Zi Michael, Jhund, Pardeep S., de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Desai, Akshay S., Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.

Published
2022
Full Text
View/download PDF

20. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

Author

Butt, Jawad H., Kondo, Toru, Jhund, Pardeep S., Comin-Colet, Josep, de Boer, Rudolf A., Desai, Akshai S., Hernandez, Adrian F., Inzucchi, Silvio E., Janssens, Stefan P., Kosiborod, Mikhail N., Lam, Carolyn S.P., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe, Petersson, Magnus, Shah, Sanjiv J., Thierer, Jorge, Vaduganathan, Muthiah, Verma, Subodh, Wilderäng, Ulrica, Claggett, Brian L., Solomon, Scott D., and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

22. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction

Author

Cunningham, Jonathan W., Vaduganathan, Muthiah, Claggett, Brian L., Kulac, Ian J., Desai, Akshay S., Jhund, Pardeep S., de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., McGrath, Martina M., O’Meara, Eileen, Wilderäng, Ulrica, Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.

Published
2022
Full Text
View/download PDF

23. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction

Author

Butt, Jawad H., Dewan, Pooja, Jhund, Pardeep S., Anand, Inder S., Atar, Dan, Ge, Junbo, Desai, Akshay S., Echeverria, Luis E., Køber, Lars, Lam, Carolyn S.P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Rouleau, Jean L., Sim, David, Van Veldhuisen, Dirk J., Vrtovec, Bojan, Zannad, Faiez, Zile, Michael R., Gong, Jianjian, Lefkowitz, Martin P., Rizkala, Adel R., Solomon, Scott D., and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

24. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF

Author

Butt, Jawad H., Dewan, Pooja, DeFilippis, Ersilia M., Biering-Sørensen, Tor, Docherty, Kieran F., Jhund, Pardeep S., Kosiborod, Mikhail N., Martinez, Felipe A., Bengtsson, Olof, Johansen, Niklas Dyrby, Langkilde, Anna Maria, Sjöstrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Sabatine, Marc S., Køber, Lars, Fiuzat, Mona, and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

25. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Yeoh, Su Ern, Docherty, Kieran F., Campbell, Ross T., Jhund, Pardeep S., Hammarstedt, Ann, Heerspink, Hiddo J.L., Jarolim, Petr, Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Solomon, Scott D., Sjöstrand, Mikaela, Bengtsson, Olof, Greasley, Peter J., Sattar, Naveed, Welsh, Paul, Sabatine, Marc S., Morrow, David A., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

31. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

Author

Docherty, Kieran F., Anand, Inder S., Chiang, Chern-En, Chopra, Vijay K., Desai, Akshay S., Kitakaze, Masafumi, Verma, Subodh, Vinh, Pham N., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Langkilde, Anna Maria, Jhund, Pardeep S., and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

34. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial

Author

Solomon, Scott D., Vaduganathan, Muthiah, Claggett, Brian L., de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Belohlavek, Jan, Chiang, Chern-En, Willem Borleffs, C. Jan, Comin-Colet, Josep, Dobreanu, Dan, Drozdz, Jaroslaw, Fang, James C., Alcocer Gamba, Marco Antonio, Al Habeeb, Waleed, Han, Yaling, Cabrera Honorio, Jose Walter, Janssens, Stefan P., Katova, Tsvetana, Kitakaze, Masafumi, Merkely, Bela, O’Meara, Eileen, Kerr Saraiva, Jose Francisco, Tereschenko, Sergey N., Thierer, Jorge, Vardeny, Orly, Verma, Subodh, Vinh, Pham Nguyen, Wilderäng, Ulrica, Zaozerska, Natalia, Lindholm, Daniel, Petersson, Magnus, and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

37. Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease.

Author

Zahir Anjum, Deewa, Bonde, Anders N., Fosbol, Emil, Hartwell Garred, Caroline, Gislason, Gunnar, Elmegaard, Mariam, Knigge, Pauline, Torp‐Pedersen, Christian, Andersson, Charlotte, Pfeffer, Marc A., Jhund, Pardeep S., McMurray, John J.V., Petrie, Mark C., Kober, Lars, and Schou, Morten

Subjects
CHRONIC kidney failure, HEART failure patients, GLOMERULAR filtration rate, EPIDERMAL growth factor receptors, HEART failure
Abstract

Aims: Chronic kidney disease (CKD) is a well‐established risk factor for heart failure (HF); however, patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 have been systematically excluded from clinical trials. This study investigated the incidence of HF and kidney outcomes in HF patients with and without advanced CKD, that is, eGFR < 30. Methods: From nationwide registries, HF patients were identified from 2014 to 2018 and categorized into three groups according to baseline eGFR (eGFR ≥ 60, 60 > eGFR ≥ 30 and eGFR < 30). The incidence of primary outcomes (all‐cause mortality, HF hospitalization, end‐stage kidney disease and sustained 50% eGFR decline) was estimated using cumulative incidence functions. Results: Of the 21 959 HF patients included, the median age was 73.9 years, and 30% of patients had an eGFR between 30 and 60 and 7% had an eGFR < 30. The 4 year incidence of all‐cause mortality was highest for patients with eGFR < 30 (28.3% for patients with eGFR ≥ 60, 51.6% for patients with 60 > eGFR ≥ 30 and 72.2% for patients with eGFR < 30). The 4 year incidence of HF hospitalization was comparable between the groups (25.8%, 29.8% and 26.1% for patients with eGFR ≥ 60, 60 > eGFR ≥ 30 and eGFR < 30, respectively). For patients with eGFR < 30, kidney outcomes were four times more often the first event than patients with eGFR > 30 (4 year incidence of kidney outcome as the first event was 5.0% for eGFR ≥ 60, 4.8% for 60 > eGFR ≥ 30 and 20.1% for eGFR < 30). Conclusions: Patients with advanced CKD had a higher incidence of mortality and poorer kidney outcomes than those without advanced CKD, but a similar incidence of HF hospitalizations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design.

Author

Carberry, Jaclyn, Petrie, Mark C., Lee, Matthew M.Y., Brooksbank, Katriona, Campbell, Ross T., Good, Richard, Jhund, Pardeep S., Kellman, Peter, Lang, Ninian N., Mangion, Kenneth, Mark, Patrick B., McConnachie, Alex, McMurray, John J.V., Meyer, Barbara, Orchard, Vanessa, Shaukat, Aadil, Watkins, Stuart, Welsh, Paul, Sattar, Naveed, and Berry, Colin

Subjects
LEFT ventricular dysfunction, MYOCARDIAL infarction, SODIUM-glucose cotransporter 2 inhibitors, BODY surface area, HEART failure
Abstract

Aims: Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can lead to the development of heart failure and death. The early addition of a sodium‐glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients. Methods and results: EMpagliflozin to PREvent worSening of left ventricular volumes and Systolic function after Myocardial Infarction (EMPRESS‐MI) is a randomized, double‐blind, placebo‐controlled, multi‐centre trial designed to assess the effect of empagliflozin on cardiac remodelling evaluated using cardiovascular magnetic resonance (CMR) in 100 patients with left ventricular systolic dysfunction following MI. Eligible patients were those ≥12 h and ≤14 days following acute MI, with an LVEF <45% by CMR. Patients were randomized to empagliflozin 10 mg once a day or matching placebo. The primary outcome will be change in left ventricular end‐systolic volume indexed to body surface area over 24 weeks from randomization. Secondary endpoints include measures of left ventricular and atrial volumes, left ventricular mass, LVEF, and circulating cardiac biomarkers. Conclusions: EMPRESS‐MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with left ventricular systolic dysfunction after an acute MI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction.

Author

Docherty, Kieran F., McMurray, John J.V., Kalra, Paul R., Cleland, John G.F., Lang, Ninian N., Petrie, Mark C., Robertson, Michele, and Ford, Ian

Subjects
SODIUM-glucose cotransporter 2 inhibitors, VENTRICULAR ejection fraction, HEART failure patients, IRON deficiency, HEART failure
Abstract

Aims: To explore the potential interaction between use of SGLT2 inhibitors and the increase in haemoglobin in patients randomized to intravenous iron or the control group in the IRONMAN (Effectiveness of Intravenous Iron Treatment versus Standard Care in Patients with Heart Failure and Iron Deficiency) trial. Methods and results: This was a post hoc exploratory analysis of the IRONMAN trial which randomized patients with heart failure, a left ventricular ejection fraction (LVEF) ≤ 45% and iron deficiency (transferrin saturation <20% or ferritin <100 μg/L) to open label intravenous ferric derisomaltose or usual care. Of the 1137 randomized patients, 29 (2.6%) were taking an SGLT2 inhibitor at baseline. The mean (SD) change in haemoglobin from baseline at 4 weeks in those taking an SGLT2 inhibitor at baseline was 1.3 (1.2) g/dL in patients randomized to ferric derisomaltose and 0.1 (0.7) g/dL in the usual care group; between‐group difference = 1.0 g/dL (95% CI 0.1, 1.8). The equivalent numbers in the no SGLT2 inhibitor group were 0.6 (0.9) g/dL in those randomized to ferric derisomaltose and 0.1 (0.8) g/dL in the usual care group; between‐group difference = 0.4 g/dL (95% CI 0.3, 1.6); interaction P value = 0.10. No patient receiving an SGLT2 inhibitor at baseline developed polycythaemia during follow‐up (defined as haemoglobin >16.5 g/dL [men] or >16 g/dL [women]). Conclusions: In the IRONMAN trial, there was a trend to a greater increase in haemoglobin with ferric derisomaltose in iron‐deficient patients taking an SGLT2 inhibitor at baseline, as compared with those not taking one. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Cardiovascular‐kidney‐metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON‐HF.

Author

Lassen, Mats C.H., Ostrominski, John W., Claggett, Brian L., Packer, Milton, Zile, Michael, Desai, Akshay S., Shah, Amil M., Cikes, Maja, Merkely, Bela, Gori, Mauro, Wang, Xiaowen, Hegde, Sheila M., Pfeffer, Marc A., Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D., and Vaduganathan, Muthiah

Subjects
GLOBAL longitudinal strain, HEART failure, TYPE 2 diabetes, GLOMERULAR filtration rate, CHRONIC kidney failure, ENTRESTO
Abstract

Aims: Cardiovascular‐kidney‐metabolic (CKM) multimorbidity is prevalent among individuals with heart failure (HF), but whether cardiac structure and function, clinical outcomes, and treatment response to sacubitril/valsartan vary in relation to CKM status is unknown. Methods and results: In this PARAGON‐HF post‐hoc analysis, we evaluated the impact of CKM multimorbidity (atherosclerotic cardiovascular [CV] disease, chronic kidney disease, and type 2 diabetes) on cardiac structure and function, clinical outcomes, and treatment effects of sacubitril/valsartan versus valsartan. The primary outcome was a composite of total HF hospitalizations and CV death. Secondary outcomes included the individual components of the primary outcome and a composite kidney outcome (sustained estimated glomerular filtration rate reduction of ≥50%, end‐stage kidney disease, or kidney‐related death). At baseline, 35.2% had one CKM condition, 33.3% had two, 15.9% had three, and only 15.6% had HF alone. CKM multimorbidity was associated with higher septal and posterior wall thickness, lower global longitudinal strain, higher E/e', and worse right ventricular function. Total HF hospitalizations or CV death increased with greater CKM multimorbidity, with the highest relative risk observed with three CKM conditions (rate ratio 3.06, 95% confidence interval 2.33–4.03), compared with HF alone. Treatment effects of sacubitril/valsartan were consistent irrespective of the number of CKM conditions for the primary endpoint (pinteraction = 0.75), CV death (pinteraction = 0.82), total HF hospitalizations (pinteraction = 0.67), and the composite kidney endpoint (pinteraction = 0.99). Conclusions: Cardiovascular‐kidney‐metabolic multimorbidity was common in PARAGON‐HF and associated with adverse changes in cardiac structure and function and with a stepwise increase in risk of clinical outcomes. Treatment effects of sacubitril/valsartan were consistent irrespective of CKM burden. Clinical Trial Registration: ClinicalTrials.gov NCT01920711. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.

Author

Lam, Carolyn S.P., Køber, Lars, Kuwahara, Koichiro, Lund, Lars H., Mark, Patrick B., Mellbin, Linda G., Schou, Morten, Ely Pizzato, Patricia, Gabrielsen, Anders, Gasparyan, Samvel B., Ghiretti, Alessandro, Hartleib‐Geschwindner, Judith, Housler, Greggory J., Fanti, Paolo, Leonsson‐Zachrisson, Maria, McMurray, John J.V., and Solomon, Scott D.

Subjects
CHRONIC kidney failure, MINERALOCORTICOID receptors, GLOMERULAR filtration rate, PEPTIDES, HEART failure patients
Abstract

Aims: Many patients with heart failure (HF) have chronic kidney disease (CKD) and may not tolerate mineralocorticoid receptor antagonists. We investigated the efficacy and safety of the novel mineralocorticoid receptor modulator balcinrenone in combination with dapagliflozin in a phase 2b study. Methods and results: From January 2021 to October 2023, we randomized 133 adults with symptomatic HF, ejection fraction <60%, estimated glomerular filtration rate (eGFR) ≥30 to ≤60 ml/min/1.73 m2 and urinary albumin‐to‐creatinine ratio (UACR) ≥30 to <3000 mg/g, to receive balcinrenone 15, 50 or 150 mg/day plus dapagliflozin 10 mg/day, or dapagliflozin 10 mg/day plus placebo, for 12 weeks. Enrolment was stopped early because of slow recruitment. Relative reductions in UACR from baseline to week 12 (primary endpoint) were not significantly different between the balcinrenone plus dapagliflozin groups versus dapagliflozin plus placebo. There was no clear balcinrenone dose–response relationship. There were possible dose‐dependent increases in serum potassium levels, reduced eGFR in the highest dose group, and non‐significant trends towards reduced N‐terminal pro‐B‐type natriuretic peptide levels. Hyperkalaemia adverse events led to discontinuation in two participants receiving balcinrenone plus dapagliflozin and none in those receiving dapagliflozin plus placebo. Conclusion: While the smaller than planned sample size limits interpretation, we did not see significant reduction in UACR in patients treated with balcinrenone plus dapagliflozin compared with dapagliflozin plus placebo. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Use of medical therapy and risk of clinical events according to frailty in heart failure patients – A real‐life cohort study.

Author

Zahir Anjum, Deewa, Strange, Jarl E., Fosbøl, Emil, Garred, Caroline Hartwell, Elmegaard, Mariam, Andersson, Charlotte, Jhund, Pardeep S., McMurray, John J.V., Petrie, Mark C., Kober, Lars, and Schou, Morten

Subjects
DISEASE risk factors, ANGIOTENSIN-receptor blockers, MINERALOCORTICOID receptors, HEART failure patients, HEART failure, CLINICAL trials
Abstract

Aims: Although recent randomized clinical trials have demonstrated the advantages of heart failure (HF) therapy in both frail and not frail patients, there is insufficient information on the use of HF therapy based on frailty status in a real‐world setting. The aim was to examine how frailty status in HF patients associates with use of HF therapy and with clinical outcomes. Methods and results: Patients with new‐onset HF between 2014 and 2021 were identified using the nationwide Danish registers. Patients across the entire range of ejection fraction were included. The associations between frailty status (using the Hospital Frailty Risk Score) and use of HF therapy and clinical outcomes (all‐cause mortality, HF hospitalization, and non‐HF hospitalization) were evaluated using multivariable‐adjusted Cox models adjusting for age, sex, diagnostic setting, calendar year, comorbidities, pharmacotherapy, and socioeconomic status. Of 35 999 participants (mean age 69.1 years), 68% were not frail, 26% were moderately frail, and 6% were severely frail. The use of HF therapy was significantly lower in frailer patients. The hazard ratio (HR) for angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker initiation was 0.74 (95% confidence interval 0.70–0.77) and 0.48 (0.43–0.53) for moderate frailty and severe frailty, respectively. For beta‐blockers, the corresponding HRs were 0.74 (0.71–0.78) and 0.51 (0.46–0.56), respectively, and for mineralocorticoid receptor antagonists, 0.83 (0.80–0.87) and 0.58 (0.53–0.64), respectively. The prevalence of death and non‐HF hospitalization increased with frailty status. The HR for death was 1.55 (1.47–1.63) and 2.32 (2.16–2.49) for moderate and severe frailty, respectively, and the HR for non‐HF hospitalization was 1.37 (1.32–1.41) and 1.82 (1.72–1.92), respectively. The association between frailty status and HF hospitalization was not significant (HR 1.08 [1.02–1.14] and 1.08 [0.97–1.20], respectively). Conclusion: In real‐world HF patients, frailty was associated with lower HF therapy use and with a higher incidence of clinical outcomes including mortality and non‐HF hospitalization. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

Author

Docherty, Kieran F., Ogunniyi, Modele O., Anand, Inder S., Desai, Akshay S., Diez, Mirta, Howlett, Jonathan G., Nicolau, Jose C., O’Meara, Eileen, Verma, Subodh, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Lindholm, Daniel, Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Langkilde, Anna Maria, Jhund, Pardeep S., and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

45. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER

Author

Wang, Xiaowen, Vaduganathan, Muthiah, Claggett, Brian L., Hegde, Sheila M., Pabon, Maria, Kulac, Ian J., Vardeny, Orly, O’Meara, Eileen, Zieroth, Shelley, Katova, Tzvetana, McGrath, Martina M., Pouleur, Anne-Catherine, Jhund, Pardeep S., Desai, Akshay S., Inzucchi, Silvio E., Kosiborod, Mikhail N., de Boer, Rudolf A., Kober, Lars, Sabatine, Marc S., Martinez, Felipe A., Ponikowski, Piotr, Shah, Sanjiv J., Hernandez, Adrian F., Langkilde, Anna Maria, McMurray, John J.V., Solomon, Scott D., and Lam, Carolyn S.P.

Published
2023
Full Text
View/download PDF

48. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF

Author

Teerlink, John R., Diaz, Rafael, Felker, G. Michael, McMurray, John J.V., Metra, Marco, Solomon, Scott D., Biering-Sørensen, Tor, Böhm, Michael, Bonderman, Diana, Fang, James C., Lanfear, David E., Lund, Mayanna, Momomura, Shin-ichi, O'Meara, Eileen, Ponikowski, Piotr, Spinar, Jindrich, Flores-Arredondo, Jose H., Claggett, Brian L., Heitner, Stephen B., Kupfer, Stuart, Abbasi, Siddique A., and Malik, Fady I.

Published
2021
Full Text
View/download PDF

50. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

Author

Wheeler, David C., Toto, Robert D., Stefánsson, Bergur V., Jongs, Niels, Chertow, Glenn M., Greene, Tom, Hou, Fan Fan, McMurray, John J.V., Pecoits-Filho, Roberto, Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Umanath, Kausik, Langkilde, Anna Maria, and Heerspink, Hiddo J.L.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results